Cargando…

Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis

Inflammatory Bowel Diseases (IBDs) are characterized by chronic intestinal inflammation and fibrosis, the latter being the predominant denominator for long-term complications. Epithelial and mesenchymal 2D cultures are highly utilized in vitro models for the preclinical evaluation of anti-inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Kandilogiannakis, Leonidas, Filidou, Eirini, Drygiannakis, Ioannis, Tarapatzi, Gesthimani, Didaskalou, Stylianos, Koffa, Maria, Arvanitidis, Konstantinos, Bamias, Giorgos, Valatas, Vassilis, Paspaliaris, Vasilis, Kolios, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331310/
https://www.ncbi.nlm.nih.gov/pubmed/34354753
http://dx.doi.org/10.1155/2021/9929461
_version_ 1783732898510143488
author Kandilogiannakis, Leonidas
Filidou, Eirini
Drygiannakis, Ioannis
Tarapatzi, Gesthimani
Didaskalou, Stylianos
Koffa, Maria
Arvanitidis, Konstantinos
Bamias, Giorgos
Valatas, Vassilis
Paspaliaris, Vasilis
Kolios, George
author_facet Kandilogiannakis, Leonidas
Filidou, Eirini
Drygiannakis, Ioannis
Tarapatzi, Gesthimani
Didaskalou, Stylianos
Koffa, Maria
Arvanitidis, Konstantinos
Bamias, Giorgos
Valatas, Vassilis
Paspaliaris, Vasilis
Kolios, George
author_sort Kandilogiannakis, Leonidas
collection PubMed
description Inflammatory Bowel Diseases (IBDs) are characterized by chronic intestinal inflammation and fibrosis, the latter being the predominant denominator for long-term complications. Epithelial and mesenchymal 2D cultures are highly utilized in vitro models for the preclinical evaluation of anti-inflammatory and antifibrotic therapies. More recently, human intestinal organoids (HIOs), a new 3D in vitro model derived from pluripotent stem cells, have the advantage to closely resemble the architecture of the intestinal mucosa. However, the appropriate timing for the study of inflammatory and fibrotic responses, during HIO development, has not been adequately investigated. We developed HIOs from the human embryonic stem cell line, H1, and examined the expression of mesenchymal markers during their maturation process. We also investigated the effect of inflammatory stimuli on the expression of fibrotic and immunological mediators. Serial evaluation of the expression of mesenchymal and extracellular matrix (ECM) markers revealed that HIOs have an adequately developed mesenchymal component, which gradually declines through culture passages. Specifically, CD90, collagen type I, collagen type III, and fibronectin were highly expressed in early passages but gradually diminished in late passages. The proinflammatory cytokines IL-1α and TNF-α induced the mRNA expression of fibronectin, collagen types I and III, tissue factor (TF), and alpha-smooth muscle actin (α-SMA) primarily in early passages. Similarly, HIOs elicited strong mRNA and protein mesenchymal (CXCL10) and epithelial (CXCL1, CCL2, CXCL8, and CCL20) chemokine responses in early but not late passages. In contrast, the epithelial tight junction components, CLDN1 and JAMA, responded to inflammatory stimulation independently of the culture passage. Our findings indicate that this HIO model contains a functional mesenchymal component, during early passages, and underline the significance of the mesenchymal cells' fitness in inflammatory and fibrotic responses. Therefore, we propose that this model is suitable for the study of epithelial-mesenchymal interactions in early passages when the mesenchymal component is active.
format Online
Article
Text
id pubmed-8331310
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-83313102021-08-04 Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis Kandilogiannakis, Leonidas Filidou, Eirini Drygiannakis, Ioannis Tarapatzi, Gesthimani Didaskalou, Stylianos Koffa, Maria Arvanitidis, Konstantinos Bamias, Giorgos Valatas, Vassilis Paspaliaris, Vasilis Kolios, George Stem Cells Int Research Article Inflammatory Bowel Diseases (IBDs) are characterized by chronic intestinal inflammation and fibrosis, the latter being the predominant denominator for long-term complications. Epithelial and mesenchymal 2D cultures are highly utilized in vitro models for the preclinical evaluation of anti-inflammatory and antifibrotic therapies. More recently, human intestinal organoids (HIOs), a new 3D in vitro model derived from pluripotent stem cells, have the advantage to closely resemble the architecture of the intestinal mucosa. However, the appropriate timing for the study of inflammatory and fibrotic responses, during HIO development, has not been adequately investigated. We developed HIOs from the human embryonic stem cell line, H1, and examined the expression of mesenchymal markers during their maturation process. We also investigated the effect of inflammatory stimuli on the expression of fibrotic and immunological mediators. Serial evaluation of the expression of mesenchymal and extracellular matrix (ECM) markers revealed that HIOs have an adequately developed mesenchymal component, which gradually declines through culture passages. Specifically, CD90, collagen type I, collagen type III, and fibronectin were highly expressed in early passages but gradually diminished in late passages. The proinflammatory cytokines IL-1α and TNF-α induced the mRNA expression of fibronectin, collagen types I and III, tissue factor (TF), and alpha-smooth muscle actin (α-SMA) primarily in early passages. Similarly, HIOs elicited strong mRNA and protein mesenchymal (CXCL10) and epithelial (CXCL1, CCL2, CXCL8, and CCL20) chemokine responses in early but not late passages. In contrast, the epithelial tight junction components, CLDN1 and JAMA, responded to inflammatory stimulation independently of the culture passage. Our findings indicate that this HIO model contains a functional mesenchymal component, during early passages, and underline the significance of the mesenchymal cells' fitness in inflammatory and fibrotic responses. Therefore, we propose that this model is suitable for the study of epithelial-mesenchymal interactions in early passages when the mesenchymal component is active. Hindawi 2021-07-27 /pmc/articles/PMC8331310/ /pubmed/34354753 http://dx.doi.org/10.1155/2021/9929461 Text en Copyright © 2021 Leonidas Kandilogiannakis et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kandilogiannakis, Leonidas
Filidou, Eirini
Drygiannakis, Ioannis
Tarapatzi, Gesthimani
Didaskalou, Stylianos
Koffa, Maria
Arvanitidis, Konstantinos
Bamias, Giorgos
Valatas, Vassilis
Paspaliaris, Vasilis
Kolios, George
Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title_full Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title_fullStr Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title_full_unstemmed Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title_short Development of a Human Intestinal Organoid Model for In Vitro Studies on Gut Inflammation and Fibrosis
title_sort development of a human intestinal organoid model for in vitro studies on gut inflammation and fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331310/
https://www.ncbi.nlm.nih.gov/pubmed/34354753
http://dx.doi.org/10.1155/2021/9929461
work_keys_str_mv AT kandilogiannakisleonidas developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT filidoueirini developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT drygiannakisioannis developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT tarapatzigesthimani developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT didaskaloustylianos developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT koffamaria developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT arvanitidiskonstantinos developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT bamiasgiorgos developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT valatasvassilis developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT paspaliarisvasilis developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis
AT koliosgeorge developmentofahumanintestinalorganoidmodelforinvitrostudiesongutinflammationandfibrosis